OMNIlife science™, Inc. Announces First Clinical Use of Novel Robotic Tissue Balancing Device for OMNIBotics® Technology Platform

Posted On March 13, 2017 By OrthoSpineNews In Regulatory, Robotics /

RAYNHAM, Mass., March 13, 2017 /PRNewswire/ — OMNIlife science, Inc. (“OMNI™”), a privately-held, established medical technology company targeting the $15 billion global hip and knee replacement device market, announced today the first clinical use of a novel robotic tissue balancing device for use with OMNI’s market-leading OMNIBotics® robotic-assisted total knee replacement technology platform. The successful initial procedure took place in Sydney, Australia and was performed by Dr. Brett Fritsch, MD, FRACS, who is also a member of OMNI’s surgeon clinical evaluation and research team. The device has received the CE Mark and a 510(k) has been submitted to FDA for clearance in the United States.

The OMNIBotics system enables optimized knee implant placement using robotics driven by OMNI’s proprietary ART™ software. With more than 13,000 OMNIBotics procedures performed to date worldwide, it provides patient-specific procedures and eliminates the need for preoperative CT scans or x-rays. Intraoperative adjustments are easily made, and the precise alignment of the implant may lead to a more rapid recovery and a more natural feeling total knee replacement.¹ This new robotic tissue balancing device takes patient-specificity one step further and customizes the procedure not only from a skeletal perspective but also from a soft tissue perspective.

“The OMNIBotics tissue balancer provides dynamic real time feedback on the interplay between the soft-tissue envelope and bone cuts in Total Knee Replacement,” said Dr. Brett Fritsch. “Providing a quantitative tool to actively manage soft tissue in combination with the accuracy of a robotic bone cutting guide has the potential to be a significant step forward towards a more natural feeling knee replacement for the patient.”

“The main objective of the OMNI robotics development program is to leverage the capabilities of robotics to assist orthopaedic surgeons in improving patient outcomes at a lower overall cost for the episode of patient care,” said Rick Randall, OMNI CEO. “Our surgeon customers believe a properly aligned and balanced knee throughout the entire range of motion will lead to optimized patient outcomes. The unique capability of robotic-assisted soft tissue balancing, added to the OMNIBotics alignment of the APEX Knee™ is an exciting breakthrough that further advances our value-based outcomes goals.”

ABOUT OMNI

OMNI is a privately held company with a proprietary robotic platform, OMNIBotics®, which allows surgeons to conduct patient-specific total knee surgery designed to enhance patient satisfaction and reduce hospital costs. In addition, OMNI designs, engineers, manufactures and distributes a wide range of proprietary hip and knee implants and is focused on providing cutting edge technologies to transform outcomes in joint replacement surgery and enhance a surgeon’s ability to help patients live active and pain-free lives. For more information about OMNI, please visit www.omnils.com.

FORWARD LOOKING STATEMENTS

Statements in this press release concerning the future business, operations and prospects of OMNIlife science, Inc., including its plans specific to OMNIBotics systems, as well as statements using the terms “plans,” “believes” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors include, among others, changes in competitive conditions and pricing in OMNI’s markets, decrease in the demand for OMNI’s products, delays in OMNI’s product research and development cycles, decreases in the use of OMNI’s principal product lines or in procedure volume, unanticipated issues in complying with domestic or foreign regulatory requirements related to OMNI’s current products or securing regulatory clearance or approvals for new products or upgrades or changes to OMNI’s current products, the impact of the United States healthcare reform legislation on hospital spending and reimbursement, any unanticipated impact arising out of the securities class action or any other litigation, inquiry, or investigation brought against OMNI, increases in costs of OMNI’s sales force and distributors, and unanticipated intellectual property expenditures required to develop, market, and defend OMNI’s products. OMNI cannot guarantee any future results, levels of activity, performance or achievement. OMNI undertakes no obligation to update any of its forward-looking statements after the date of this press release.

CONTACT
Cindy Holloway, Director of Marketing Communications Phone: (508) 824-2444
cholloway@omnils.com

¹Ritter, Et al. “The Effect of Alignment and BMI on Failure of Total Knee Replacement”. J Bone Joint Surg, 2011; 93- A:1588-96.

SOURCE OMNIlife science, Inc.

Mazor Robotics to Exhibit New Mazor X™ Surgical Assurance Platform at AANS/CNS Spine Summit Meeting

Posted On March 1, 2017 By OrthoSpineNews In Robotics, Spine, Top Stories /

ORLANDO, FL–(Marketwired – March 01, 2017) – Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR), a pioneer and leader in the field of surgical guidance systems, will demo the new Mazor X system at Spine Summit 2017, the Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves in Las Vegas, March 8-11.

Visit booth #1110 during exhibit hours or attend the following special presentations to learn more about Mazor X:

Lunch Seminar: Introducing Mazor X™: Mazor Robotics’ Next-Gen System
Moderator: Dr. Michael Steinmetz
Location: Valencia Ballroom
Date: Wednesday, March 8
Time: 12:30 – 1:30 pm

“What’s New” Session: Clinical Experience of Mazor Robotics Guidance Systems and O-Arm^® Imaging in Degenerative and Deformity Cases
Faculty: Dr. Jeffrey L. Gum
Location: Demo Theater
Date: Friday, March 10
Time: 9:47 – 9:57 am

The Mazor X system consists of sophisticated 3D planning tools and an intra-op guidance system with a precision Surgical Arm indicated for implant and instrument positioning in spine surgery — the core of the Surgical Assurance Platform.

“Mazor’s core technology has been used in over 23,000 procedures. This unparalleled clinical and operating room experience has provided us with deep insight into what the surgeons want next for themselves and their patients,” said Mazor Robotics CEO Ori Hadomi. “So, we pushed the envelope, moving from a precise mechanical system, to a complete expandable platform that incorporates integrated analytics and state-of-the art guidance.”

“You plan your surgery and there is no heartache anymore,” said Orthopedic Surgeon Kornelis Poelstra, MD, PhD. “You know exactly where the screws are going to go.” Click here to watch full testimonial

Following Spine Summit, Mazor Robotics will also be exhibiting Mazor X at AAOS Annual Meeting in San Diego, March 14-18 (booth #2339).

About Mazor

Mazor Robotics (TASE: MZOR) (NASDAQ: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in an accurate and secure manner. For more information, please visit MazorRobotics.com.

Image Available: http://www.marketwire.com/library/MwGo/2017/2/28/11G131731/Images/mazor_bot-81c042b0c45195a0b5cfdad64568b31a.jpg

CONTACT INFORMATION

Mazor Robotics, Inc.
Tel: 1 (800) 80-MAZOR
Fax: (407) 591-3560
usa@mazorrobotics-us.com

Global Hip and Knee Orthopedic Surgical Robots Industry Research Report 2016 to 2022

Posted On February 27, 2017 By OrthoSpineNews In Recon, Robotics, Top Stories /

FEBRUARY 21, 2017 – RESEARCHMOZ GLOBAL PVT. LTD.

The 2016 study has 145 pages, 64 tables and figures. Worldwide Hip and Knee Orthopedic surgical robot markets are poised to achieve significant growth. The accuracy provided by the robot is not reproducible by the human surgeon, so ultimately all surgeons will want to perform the orthopedic implants using this technology.

Robot assisted medial knee arthroplasty: orthopedic surgical robots are poised to take knee and hip surgery quality far beyond what has previously been available. The quality of knee arthroplasty is improved with robotic capability. All the advantages of surgical robots carry into the Stryker Mako orthopedic reconstruction surgical products.. When the knee and hip surgical robots are used, patients have less bleeding, reduction of post-operative pain, fewer re-admissions to hospital and faster recovery. Robots support high-precision surgery. A clinic in Switzerland, La Source, has reported a reduction in the average days of hospitalization from 10 to 6.

Knee and hip surgical robots provide consistent reproducible precision. This capability is so significant for implant surgery that the robots are positioned to become the defacto standard of care for knee and hip surgery within five years. Any one getting a knee or hip replaced will demand attention to quality of life, to maintenance of lifestyle provided by a robot when they have a joint replacement.

As next generation systems, hip and knee robotic units provide a way to improve traditional orthopedic hip and knee replacement surgery. Total hip replacement surgery has evolved dramatically as advances in technology have brought improved surgical techniques. Surgical robots are a significany [art of that advance.

Once, the penetration achieves this 35% level, all orthopedic surgeons will demand that hospitals offer robotic orthopedic surgical capability because the outcomes are more predictable and better. If the hospital does not offer the robot, the surgeon will move to a more modern facility.

Knee and Hip Surgical Robots have been impacted by the reduction in insurance payments. Payment reductions have forced hospitals to start acting as businesses. The cost of delivering care has become as much a factor as providing quality care when making decisions about patient improvement in condition. Cost-cutting has been made in the supply chain. Suppliers were examined closely for quality and cost.

READ THE REST HERE

TransEnterix to Present at the RBC Capital Markets Global Healthcare Conference

Posted On February 9, 2017 By OrthoSpineNews In Robotics /

February 09, 2017

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT:TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York. The presentation is scheduled to take place at 11:00 am Eastern Time on Thursday, February 23, 2017.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance™ Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

Contacts

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1 443-213-0501
invest@transenterix.com
Or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
or
(For US) Hannah Dunning, +1 415-618-8750
TransEnterix-SVC@sardverb.com

Medtronic, Intuitive Surgical Lead Japan Surgical Navigation and Robotics Systems Market Driven by Changes in Regulatory Policy

Posted On February 2, 2017 By OrthoSpineNews In Regulatory, Robotics /

VANCOUVER, BC–(Marketwired – February 01, 2017) – According to a new series of reports on the Japanese robotics and surgical navigation market by iData Research (www.idataresearch.com), the market in the region is still in its infancy. While several systems have regular sales and a growing installed-base, a number of companies are planning to enter the market in the next several years, particularly due to recent changes in regulatory policy. The largest segment in the Japanese surgical navigation market is represented by navigation systems with orthopedic applications, accounting for nearly 50% of the total market value. As orthopedic navigation systems gain market share from competing technologies such as patient-specific cutting blocks, they will continue to make up the largest navigation segment. However, these systems will face increased competition from newer technologies, like orthopedic robotics systems.

Many orthopedic surgical navigation systems are leased; however, the growth of the orthopedic navigation systems market is driven by sales to new facilities. Market growth is expected to be fueled as applications in total knee and total hip arthroplasty increases, and partial knee arthroplasty procedures begin to use navigation technology.

“As the installed-base expands, companies will be able to increase revenues from service and maintenance,” explains Dr. Kamran Zamanian, CEO of iData. “Also, the entrance of new companies who are looking to provide navigation systems at more budget-friendly prices will expand the market to smaller facilities who, in the past, could not afford the top-of-the-line systems.”

The overall average selling price (ASP) is expected to remain stable due to newer systems entering the market both on the higher and lower ends of the price spectrum, which will stabilize the ASP as institutions upgrade. For example, ENT departments often have lower budgets for navigation systems than their high-priced neurosurgical or spinal counterparts, and the Japanese market is seeing growth in both of these segments. The spinal navigation system segment is projected to exhibit the fastest growth. Image guided systems (ISG) with spine surgery capabilities have a similar ASP to neurosurgery IGS systems as the majority of systems that can be used for neurosurgery can also be used for spine surgery, and vice versa.

Medtronic leads the Japan surgical navigation systems market. The company has established itself through brand recognition and by making systems compatible with their implant products. Medtronic competes with a number of other navigation and implant companies in Japan. Other leading competitors in the Japanese surgical navigation market include Brainlab and Stryker. Intuitive Surgical leads the Japan surgical robotics market. It remains the dominant competitor in Japan with a focus on laparoscopic approaches for a variety of procedures. As regulatory policies shift to encourage investment in this area, companies are expected to expand robotic options in other procedural areas. The surgical robotic systems market is expected to see growth on the part of Accuray and other companies.

For Further Information

More on the surgical navigation and robotics systems market in Japan can be found in a series of reports published by iData Research entitled the Japan Market Report Suite for Surgical Navigation and Robotic Systems. The report covers over 600 pages of market and business analysis on this market in Japan. The suite covers reports on the following markets: surgical navigation systems for neurosurgery, spinal surgery, ENT (ear/nose/throat), and orthopedic hip and knee applications. The segmentation for surgical robotics systems includes spinal, neurosurgery, minimally invasive surgery (MIS), radiosurgery, catheter and orthopedic robotically assisted systems.

The iData report series on robotics and surgical navigation covers the U.S., Japan, China, India, Australia, and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about robotics and surgical navigation market data or procedure data, register online or email us at info@idataresearch.netfor a Japan Market Report Suite for Surgical Navigation and Robotic Systems brochure and synopsis.

About iData Research

iData Research (www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Laparoscopy, Urology, Gynecology, Vascular Access, Endoscopy, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics, Ophthalmics, Dental Operatory Equipment and more.

CONTACT INFORMATION

Contact Info
Marvin Cidamon
Marketing Coordinator
iData Research Inc.
604-266-6933 Ext. 205
marvinc@idataresearch.net

First Mazor X™ System Utilized in Mid-Atlantic for Advanced Spine Surgery Procedure

Posted On February 2, 2017 By OrthoSpineNews In Robotics /

RESTON, VA–(Marketwired – February 02, 2017) – The award-winning spine surgeons at Virginia Spine Institute are the first in the Mid-Atlantic region to utilize the Mazor X™ System, a transformative robotic platform for spine surgery. Dr. Christopher Good, Dr. Thomas Schuler and Dr. Colin Haines teamed up to perform a spinal fusion with the new Mazor X™ System which utilizes enhanced analytical tools, precision guidance, optical tracking, and intra-operative verification to make spine surgery safer and less invasive. This latest advancement in spinal surgery was developed at Reston Hospital Center.

“I am very excited to offer the new Mazor X™ System’s robotic technology to our patients,” says Dr. Christopher R. Good, Spine Surgeon and Director of Research at Virginia Spine Institute. “We are proud to have performed the first and the most advanced robotic spine surgery in the Mid-Atlantic region and to be able to offer robotic surgery to our patients both for minimally invasive spine surgery and scoliosis reconstruction. Our research is already showing that robotic surgery can decrease intra-operative radiation to patients in the operating room, as well as improve accuracy of surgery and decrease patient complications. The new Mazor X™ System represents the future of robotic spine surgery and will lead to many future breakthroughs by combining robotic surgery with intra-operative spinal navigation and increase the number and types of surgeries we can perform with robot guidance.”

The new Mazor X™ System, manufactured by Mazor Robotics Ltd., represents a breakthrough and improvement from the original Renaissance^® system. Mazor commercially launched the FDA-cleared platform during the North American Spine Society annual meeting in October 2016.

Through their leadership and vast experience, Virginia Spine Institute is reshaping the future of spine surgery by improving patient safety and reducing recovery time. Virginia Spine Institute continues to pioneer alternate methods of utilizing technology to more efficiently perform complex spinal procedures. With the latest release of the Mazor X™ System comes improved surgical accuracy while incorporating a combination of robotics and live intra-operative navigation.

About Virginia Spine Institute: Virginia Spine Institute is an award-winning medical practice in the Washington, DC metro area solely dedicated to spinal health care. For 25 years they have improved the lives of over 80,000 patients suffering from back or neck pain conditions. This comprehensive spine center provides convenience of specialty care with the top experts from multiple specialties of spinal health care under one roof. Custom treatment options include non operative care, pain management, physical therapy, and when necessary surgical intervention, including minimally invasive, laser and robot-guided procedures. For more information about Virginia Spine Institute visit SpineMD.com.

Image Available: http://www.marketwire.com/library/MwGo/2017/2/2/11G129207/Images/VSI_MAZOR_2-c3bbfffa5e479f76bb217178ecb78a5e.JPG
Image Available: http://www.marketwire.com/library/MwGo/2017/2/2/11G129207/Images/MAZOR_X-a1980a153591a5eda1ef1b217dc8e1f0.JPG

CONTACT INFORMATION

Contact:
Erin Orr
Communications Director
Virginia Spine Institute
Tel: 703.709.1114 x 180
Email: Email contact

SpineMD.com

Mazor Robotics Receives Order for Three Mazor X Systems from a Leading Mid-Atlantic Health Care Organization

Posted On December 22, 2016 By OrthoSpineNews In Robotics /

December 22, 2016

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE:MZOR; NASDAQGM:MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced a three-system order for the Mazor X from a first-time customer, a leading mid-Atlantic health care organization which will install the systems at three of its medical centers.

“The level of enthusiasm following the launch of the Mazor X system at the NASS conference in October remains high and continues to generate considerable momentum,” commented Ori Hadomi, Chief Executive Officer. “This is the second multi-system order during the fourth quarter, both representing new customers, and demonstrating the co-marketing activities with our commercial partner are increasing the market’s awareness for our advanced surgical guidance systems.”

The Company will announce the total number of system orders for the fourth quarter on January 5, 2017.

About Mazor Robotics

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the market momentum for the Mazor X system, the benefits of the cooperation with Mazor’s commercial partner, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Doug Sherk, 415-652-9100
dsherk@evcgroup.com

TransEnterix Opens Robotic Training and Research & Development Center in Milan

Posted On December 15, 2016 By OrthoSpineNews In Robotics /

December 15, 2016

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the opening of a new European training and research and development center in Milan, Italy. The facility, to be called the TransEnterix Milan Robotic Surgery Center, was inaugurated on December 15, 2016 in a special ceremony. It is part of the technology and research village next to the University Milano-Bicocca campus.

“The Senhance Surgical Robot has strong development roots in the innovation corridor found in Lombardy and Italy,” said Todd M. Pope, President and CEO at TransEnterix. “We are pleased to make this investment to create a world-class center for robotic surgical training and to continue our research and development in Milan, which will bring surgeons and researchers from across the globe together to help create the next wave of robotic surgery.”

The new robotic center will feature an integrated demonstration operating theater, robotic training and development systems, and facilities for hosting large groups. It will also serve as the Company’s European research and development facility that will further enable research collaborations with the European Union’s Joint Research Center, academic institutions and industry partners across Europe.

A number of surgeons that have pioneered the clinical use of this new system for robotic surgery and senior executives from TransEnterix were present, along with representatives of healthcare industry associations and government. The event was hosted at the new TransEnterix Milan Robotic Surgery Center, and following remarks by the special guests, participants were able to experience the Senhance Surgical System and tour the facility.

About TransEnterix

Forward Looking Statements

This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether our European training and research development center in Milan, Italy will be a world-class center for robotic training and research and development. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1-443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1-415-618-8750
TransEnterix-SVC@sardverb.com

Microbot completes merger with Stem Cell

Posted On November 30, 2016 By OrthoSpineNews In Financial, Robotics /

29/11/2016, Gali Weinreb

Israeli company Microbot, which three months ago announced its merger into Nasdaq-listed US company Stem Cell, yesterday announced that the merger had been completed. Microbot was founded as investment company MEDX Ventures Group, led by Harel Gadot and based on technology developed by Prof. Moshe Shoham, who also developed the technology of Mazor Robotics Ltd. (Nasdaq: MZOR; TASE:MZOR), a company with a $550 million market cap.

Microbot develops miniature robots. The companies first app is for cleaning drainage pipes in the body, for example in the urethra or the brain, thereby removing the necessity for surgery to replace them. The miniature robot functions in the same way as a robot that cleans swimming pools or homes. It is made of titanium, and has arms that move around it. It can be controlled from outside the body and directed within the urethra, so that accumulations of dirt are released, and can be swept out of the drain.

In the future, the product is likely to also prove suitable for cleaning plaque from blood vessels in order to prevent heart attacks and stroke and obviate the need for a balloon or stent. More remote apps include a robot with a camera for taking photographs within the body (like Given Imaging’s camera pill, but with the added capability of controlling the location and camera angle) and release of a drug in a specific place.

READ THE REST HERE

Mazor Robotics Announces the Election of Yuval Yanai to its Board of Directors

Posted On November 29, 2016 By OrthoSpineNews In Robotics /

November 29, 2016

CAESAREA, Israel–(BUSINESS WIRE)–Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced that Mr. Yuval Yanai, a medical device industry veteran, has been elected to the Company’s Board of Directors, effective immediately.

Mr. Yanai is a senior executive, who brings over 30 years of experience to Mazor. Currently Mr. Yanai serves as a Director in two publicly-traded companies listed on NASDAQ Global Market, Macrocure Ltd. and Check-Cap Ltd. Mr. Yanai also serves as a Director in two publicly traded companies listed on the Tel Aviv Stock Exchange, Medical Compression Systems (D.B.N) Ltd. and Clal Biotechnology Industries Ltd. In addition, Mr. Yanai serves as a Director of Haddasah Medical Center, Standard & Poors Maalot, Compulab Ltd. and Efranat Ltd. Mr. Yanai also acts as the Chairman of Endobetix Ltd. and the Israeli Fund for UNICEF. From 2005 through 2014, Mr. Yanai held the positions of Senior Vice President and Chief Financial Officer of Given Imaging Ltd., a developer and manufacturer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract. Given Imaging Ltd. was sold to Covidien Ltd. for $1 billion in 2014. Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University.

“I am pleased to welcome Yuval to Mazor’s Board of Directors. His experience with industry and publicly-traded companies enhances our Board of Directors as we seek to further leverage two key recent accomplishments – the strategic agreements signed in May with Medtronic and the successful October launch of the Mazor X system,” commented Jonathan Adereth, Chairman of Mazor’s Board of Directors.

“Mazor’s performance and commitment to innovation have contributed to its position as the market leader in guidance systems for spine surgeries. I am looking forward to working with the Board and being part of Mazor’s continued success,” commented Mr. Yanai.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary technologies and products aimed at redefining the gold standard of quality care. Mazor Robotics Guidance Systems enable surgeons to conduct spine and brain procedures in a precise manner. For more information, please visit http://www.MazorRobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. For example, we use forward-looking statements when we discuss our plan to further leverage our two key accomplishments – the Medtronic agreement and the overwhelmingly positive response to the Mazor X launch, and when we discuss our mission to continue to transform and redefine the standard of care for spine surgeries. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on May 2, 2016 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

U.S. Contacts:
EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Doug Sherk, 646-445-4800
dsherk@evcgroup.com

Robotics

Related Links

CONTACT INFORMATION

Contacts

CONTACT INFORMATION

CONTACT INFORMATION

Contacts

Contacts

Contacts